![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
CHDR, will conduct and manage the proposed clinical study, titled “A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Activity of Repeated Intranasal Administration of Ampligen (Poly I:Poly C12U) in Healthy Subjects.
Lead Product(s): Rintatolimod
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampligen
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Aim ImmunoTech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 29, 2021